Drugs / TetraVax-DV-TV003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06805487 | Sep 2024 → Sep 2025 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03416036 | Nov 2017 → Jan 2019 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02021968 | Nov 2013 → Mar 2015 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TetraVax-DV-TV003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416036 ↗ |
| Known as | TV003 | “a single dose of a live attenuated recombinant tetravalent dengue vaccine (TetraVax-DV-TV003, referred to as TV003)” NCT03416036 ↗1“TetraVax-DV-TV003 (TV003)” NCT06805487 ↗ |
| Modality | Vaccine | “live attenuated recombinant tetravalent dengue virus vaccine” NCT02021968 ↗ |
| Route | Subcutaneous | “delivered by subcutaneous injection in the deltoid region of the upper arm” NCT02021968 ↗ |